arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

bioAffinity Technologies, Inc.

BIAF
$0.51 ▼ -0.02 (-2.91%) at close
Industrials ·Services-Commercial Physical & Biological Research ·USServices-Commercial Physical & Biological Research
22 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

bioAffinity Technologies, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.3M
Dividend Yield
Revenue Growth -27.1%
Op. Margin -267.6%
ROIC -78.0%
FCF / Share $-0.72
Trailing P/E
Price / Book 0.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

22-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.35M
↓ -27.1%
Net Income Profit after all expenses
$-3.63M
↓ -36.5%
Operating Margin Operating profit as % of sales
-267.6%
↓ -35.9% 1th
FCF / Share Free cash flow per share
$-0.72
↓ -590.9%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
2
Financial Health
51
Cash Quality
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 22 quarters